Cannabidiol as an add-on drug improves QoL in epilepsy I AES

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Based upon preliminary analyses, cannabidiol (CBD) as an add-on drug for the treatment of pharmacoresistant epilepsy in a pediatric population does not appear to cause adverse effects involving cognition or adaptive function in patients who completed 1 year of treatment.

Why ...